查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608031

人類狂犬病疫苗市場：按細胞株類型、給藥途徑、應用、分銷管道 - 全球預測 2025-2030

Human Rabies Vaccines Market by Cell Line Type (BHK Cells, Chick Embryo Cells, Vero Cell), Route of Administration (Intravenous, Subcutaneous), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年人類狂犬病疫苗市場估值為10.1億美元，預計到2024年將達到10.5億美元，複合年成長率為4.51%，到2030年達到13.7億美元。

人類狂犬病疫苗對於預防狂犬病至關重要，狂犬病是一種致命的病毒性疾病，透過被感染動物的咬傷或抓傷傳播。狂犬病疫苗覆蓋範圍包括暴露前預防（特別是針對獸醫和前往流行地區的旅行者等高危險群）和針對咬傷受害者的暴露後預防。這些疫苗的需求是因為症狀出現後的死亡率接近 100%，這突顯了它們在全球公共衛生中的重要作用。主要最終用戶是醫療機構、獸醫醫院和旅行診所，它們在緊急情況和需要預防性干預的情況下得到高度利用。

主要市場統計
基準年[2023] 10.1億美元
預計年份 [2024] 10.5億美元
預測年份 [2030] 13.7億美元
複合年成長率（%） 4.51%

人類狂犬病疫苗市場受到多種因素的影響，例如對該疾病的認知不斷提高以及政府加強疫苗接種計劃的力度。此外，發展中地區醫療基礎設施的擴張帶來了巨大的成長機會。特別是，對預防性醫療保健的日益重視和生物技術的進步為創新提供了肥沃的土壤。還有機會開發需要更少劑量或不需要針頭的疫苗，這將提高可及性和依從性。

然而，該市場面臨局限性，例如疫苗生產高成本、分銷的物流挑戰（尤其是在農村地區）以及來自替代預防和治療藥物的競爭。另一個挑戰是潛在的副作用和錯誤訊息可能會阻礙疫苗接種並阻礙市場滲透。

創新將由重點開發更有效、更易於管理的疫苗以及改進儲存解決方案以提高供應鏈效率來推動。此外，單劑量疫苗或具有延長免疫持續時間的疫苗的開發可能會徹底改變該領域。該市場的特點是高度監管，注重安全性和有效性，這既激勵了公司，也限制了他們的營運靈活性。最終，利用與政府和非政府組織的夥伴關係、投資教育宣傳活動並推動技術進步的公司可能會利用人類狂犬病疫苗市場不斷發展的格局。

市場動態：揭示快速發展的人類狂犬病疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變人類狂犬病疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 狂犬病死亡率增加
    • 寵物和流浪狗的增加
    • 寵物疫苗接種率低，缺乏寵物管理服務
  • 市場限制因素
    • 偏遠地區疫苗供應不足
  • 市場機會
    • 活性化研發活動以推出有效的疫苗
    • 疫苗製造領域新參與企業增加
  • 市場挑戰
    • 新興國家的意識下降

波特五力：駕馭人類狂犬病疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解人類狂犬病疫苗市場的外部影響

外部宏觀環境因素在塑造人類狂犬病疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解人用狂犬病疫苗市場的競爭狀況

對人類狂犬病疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣人類狂犬病疫苗市場供應商的績效評估

FPNV 定位矩陣是評估人類狂犬病疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了人類狂犬病疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對人類狂犬病疫苗市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 狂犬病死亡率增加
      • 寵物和流浪狗的增加
      • 寵物疫苗接種率低，缺乏寵物管理服務
    • 抑制因素
      • 偏遠地區疫苗供不應求
    • 機會
      • 擴大研發活動引進有效的疫苗
      • 疫苗生產新市場進入增加
    • 任務
      • 新興國家的意識下降
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依細胞株類型分類的人用狂犬病疫苗市場

  • BHK細胞
  • 雞胚細胞
  • 維洛塞爾

第7章 人類狂犬病疫苗市場：依給藥途徑分類

  • 靜脈
  • 皮下的

第8章人用狂犬病疫苗市場：依應用分類

  • 暴露後預防
  • 暴露前預防

第9章人用狂犬病疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲人類狂犬病疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區人用狂犬病疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲人用狂犬病疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Cadila Pharmaceuticals Ltd.
  • CSC Pharmaceutical International
  • Indian Immunologicals Limited
  • Merck & Co Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India
  • Virbac
  • Wyeth, LLC
Product Code: MRR-710B1F0AC439

The Human Rabies Vaccines Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.05 billion in 2024, and is projected to grow at a CAGR of 4.51%, to USD 1.37 billion by 2030.

Human rabies vaccines are critical in preventing the fatal viral disease of rabies, transmitted through bites or scratches by infected animals. The scope of rabies vaccines encompasses both pre-exposure prophylaxis, especially for high-risk individuals such as veterinarians or travelers to endemic regions, and post-exposure prophylaxis for bite victims. The necessity of these vaccines stems from the near 100% mortality rate once symptoms appear, highlighting the essential role they play in global public health. The primary end-users are healthcare facilities, veterinary clinics, and travel clinics, with substantial applications in scenarios necessitating emergency or preventive interventions.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.05 billion
Forecast Year [2030] USD 1.37 billion
CAGR (%) 4.51%

The market for human rabies vaccines is influenced by several factors, including rising awareness about the disease and increasing government initiatives for immunization programs. Furthermore, the expansion of healthcare infrastructure in developing regions presents significant growth opportunities. Notably, the growing emphasis on preventive healthcare and advances in biotechnology provide a fertile ground for innovation. Opportunities also lie in developing vaccines that require fewer doses or are needle-free, thus improving accessibility and adherence.

However, the market faces limitations, including high costs of vaccine production, logistical challenges in distribution, especially in rural areas, and competition from alternative prophylactics and treatments. Challenges also include potential adverse reactions and misinformation leading to vaccine hesitancy, which can hinder market penetration.

Innovation can thrive by focusing on the development of more effective, easily administrable vaccines and improved storage solutions to enhance supply chain efficiency. Also, research into creating single-shot vaccines or those with extended immunity duration could revolutionize the field. This market is characterized by its highly regulated nature, with an emphasis on safety and efficacy, which can both motivate and restrict operational flexibility for companies. Ultimately, businesses that leverage partnerships with governments and NGOs, invest in education campaigns, and drive technological advancements will likely capitalize on the evolving landscape of the human rabies vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Rabies Vaccines Market

The Human Rabies Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of mortality due to rabies
    • Increasing number of pets and stray dogs
    • Lower rate of immunization in pets and lack of pet management services
  • Market Restraints
    • Dearth of vaccine supply in remote areas
  • Market Opportunities
    • Proliferation in research and development activities to introduce effective vaccine
    • Rising entry of new market players in the production of vaccine
  • Market Challenges
    • Reduced awareness in emerging economies

Porter's Five Forces: A Strategic Tool for Navigating the Human Rabies Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Rabies Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Rabies Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Rabies Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Rabies Vaccines Market

A detailed market share analysis in the Human Rabies Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Rabies Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Rabies Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Rabies Vaccines Market

A strategic analysis of the Human Rabies Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Rabies Vaccines Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic A/S, Bharat Biotech International Limited, Cadila Pharmaceuticals Ltd., CSC Pharmaceutical International, Indian Immunologicals Limited, Merck & Co Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Serum Institute of India, Virbac, and Wyeth, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Rabies Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cell Line Type, market is studied across BHK Cells, Chick Embryo Cells, and Vero Cell.
  • Based on Route of Administration, market is studied across Intravenous and Subcutaneous.
  • Based on Application, market is studied across Post Exposure Prophylaxis and Pre Exposure Prophylaxis.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of mortality due to rabies
      • 5.1.1.2. Increasing number of pets and stray dogs
      • 5.1.1.3. Lower rate of immunization in pets and lack of pet management services
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of vaccine supply in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Proliferation in research and development activities to introduce effective vaccine
      • 5.1.3.2. Rising entry of new market players in the production of vaccine
    • 5.1.4. Challenges
      • 5.1.4.1. Reduced awareness in emerging economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Rabies Vaccines Market, by Cell Line Type

  • 6.1. Introduction
  • 6.2. BHK Cells
  • 6.3. Chick Embryo Cells
  • 6.4. Vero Cell

7. Human Rabies Vaccines Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Human Rabies Vaccines Market, by Application

  • 8.1. Introduction
  • 8.2. Post Exposure Prophylaxis
  • 8.3. Pre Exposure Prophylaxis

9. Human Rabies Vaccines Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Human Rabies Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Human Rabies Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Human Rabies Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bavarian Nordic A/S
  • 2. Bharat Biotech International Limited
  • 3. Cadila Pharmaceuticals Ltd.
  • 4. CSC Pharmaceutical International
  • 5. Indian Immunologicals Limited
  • 6. Merck & Co Inc.
  • 7. Novartis International AG
  • 8. Pfizer Inc.
  • 9. Sanofi SA
  • 10. Serum Institute of India
  • 11. Virbac
  • 12. Wyeth, LLC

LIST OF FIGURES

  • FIGURE 1. HUMAN RABIES VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN RABIES VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN RABIES VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN RABIES VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY BHK CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CHICK EMBRYO CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VERO CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2023